01-09-2023 | Cabozantinib | Case report
Cabozantinib/nivolumab
Fulminant type I diabetes mellitus: case report
Published in: Reactions Weekly | Issue 1/2023
Login to get accessExcerpt
Author Information-
* death
-
* life-threatening
-
* hospitalisation
-
* disability
-
* congenital anomaly
-
* other medically important event